|View printer-friendly version|
April 30, 2015, Dallas, Texas: AveXis, Inc., a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases, today announced that John Carbona has resigned from his position as CEO. Mr. Carbona will remain a Director of AveXis. This announcement is the result of a succession plan that has been in process as AveXis advances the clinical development of its lead program for the treatment of Spinal Muscular Atrophy (SMA).
AveXis’ Board of Directors has implemented a plan to build the company’s management team to support its growth and the advancement of its lead development program for the treatment of SMA. The company has engaged a leading executive recruiting firm and initiated a search for a Chief Executive Officer. Mr. Harkey will serve as Executive Chairman of AveXis in the interim.
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today’s world.
About AveXis, Inc.
AveXis is a clinical-stage gene therapy company establishing key industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus. For more information regarding AveXis, please visit www.avexis.com.